News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Corporation Respiratory Research Pipeline


5/8/2012 11:14:29 AM

RIDGEFIELD, Conn., May 8, 2012 /PRNewswire/ -- Boehringer Ingelheim will present the latest data from its respiratory research pipeline at the Annual International Conference of the American Thoracic Society (ATS 2012), in San Francisco, CA, May 18 - 23. The 14 abstracts include results from a dose-ranging study evaluating tiotropium in subjects with moderate persistent asthma, additional analyses of data from the Phase II TOMORROW trial (To Improve Pulmonary Fibrosis with BIBF 1120), and results from a Phase II trial on the long-acting b2-agonist olodaterol in patients with COPD.

Boehringer Ingelheim's abstracts in respiratory research can be accessed through the ATS website, http://conference.thoracic.org. The Boehringer Ingelheim data will remain under embargo until the date and time that the data are presented (see details below). The ATS International Conference is one of the largest gatherings of pulmonary, critical care and sleep clinicians and researchers in the world, with 13 thousand attendees from 95 countries last year.

Collectively, these data underscore the company's focus on finding answers to the challenges faced by patients living with lung disease.

Tiotropium

Title

Lead Author

Presentation details

Dose-Ranging Study Of

Tiotropium As Treatment

For Moderate Persistent

Asthma In Adolescents

C. Vogelberg

Scientific Abstract# 305

Date: Tuesday, May 22

Time: 8:15 a.m. 10:45 a.m.

PDT / 11:15 a.m. 1:45 p.m.

EDT

BIBF 1120

Title

Lead Author

Presentation details

Treatment Of IPF With The

Tyrosine Kinase Inhibitor

BIBF 1120: Patient-

Reported Outcomes

In The TOMORROW Trial

K.K. Brown

Oral Presentation

Date: Monday, May 21

Time: 2:00 p.m 4:30 p.m.

(data presented at 2:45 p.m.)

PDT / 5:00 p.m. 7:30 p.m.

(data presented at 5:45 p.m.) EDT

Efficacy of the Tyrosine

Kinase Inhibitor BIBF 1120

in Patients with IPF:

Consistent Pattern of

Primary Endpoint Results

in Sensitivity Analyses of

the TOMORROW trial

L. Richeldi

Oral Presentation

Date: Monday, May 21

Time: 2:00 p.m 4:30 p.m.

(data presented at 2:30 p.m.)

PDT / 5:00 p.m. 7:30 p.m.

(data presented at 5:30 p.m.) EDT

Olodaterol

Title

Lead Author

Presentation details

Comparison Of 24-Hour

FEV1 Profile For Once-

Daily Versus Twice-Daily

Treatment With

Olodaterol, A Novel Long-

Acting b2-Agonist, In

Patients With COPD

G. Joos

Thematic Poster # D60

Date: Monday, May 21

Time: 10:45 a.m 12:30 p.m.

PDT / 1:45 p.m. 3:30 p.m.

EDT

Lung Function

Title

Lead Author

Presentation details

Lung Function And

Exercise Impairment In

Patients With GOLD Stage

I And II COPD

D. E. O'Donnell

Thematic Poster # G74

Date: Wednesday, May 23

Time: 8:15 a.m. 4:30 p.m.

PDT / 11:15 a.m. 7:30 p.m. EDT

Poster Discussion from

10:45 a.m. 12:30 p.m. PDT /

1:45 p.m. 3:30 p.m. EDT

Boehringer Ingelheim: Leading respiratory forward

Treatment of respiratory diseases has been a major area of focus for Boehringer Ingelheim for more than 90 years and significant resources are dedicated to research in this field. In addition to new possible treatment options for COPD, Boehringer Ingelheim has also branched out into developing treatment options for other airway diseases, including asthma, lung cancer, idiopathic pulmonary fibrosis and other respiratory diseases.

About Boehringer Ingelheim Pharmaceuticals, Inc.

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim group of companies.

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.

As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.

In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales.

For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.

SOURCE Boehringer Ingelheim


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES